In a fit of boundless national optimism, Peugeot and Renault (and a few years later Volvo) teamed up to make a new V8 for good power and performance. But that's not what the world got. We welcomed in ...

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), ...

With the rare pediatric disease and medical countermeasure priority review voucher (PRV) programs set to expire by 2022 and 2023, respectively, the Government Accountability Office (GAO) released a ...

Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority ...

While the price of just about everything has increased over the last six years in the U.S., the same can’t be said for the cost of an FDA priority review voucher. Just ask Sarepta Therapeutics. Since ...

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. Bavarian Nordic has reached an agreement to sell a priority review voucher (PRV) ...

The Senate Health, Education, Labor & Pensions committee on Wednesday advanced seven bills, including one that would reauthorize the rare pediatric priority review voucher (PRV) program through 2022, ...

PRV RENAMED: What's in a name? Apparently something, at least in the view of the U.S. Air Force, which says it is changing the name of the Personnel Recovery Vehicle (PRV) program to Combat Search and ...

DENVER, Aug. 28, 2019 /PRNewswire/ — Platte River Equity (“Platte River”) is pleased to announce the sale of its portfolio company, PRV Metals, LLC (“PRV Metals” or the “Company’), to Tinicum L.P.